204 related articles for article (PubMed ID: 25992351)
1. Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.
Ali Shah SI
South Asian J Cancer; 2015; 4(2):95-7. PubMed ID: 25992351
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.
Phillips I; Shah SI; Duong T; Abel P; Langley RE
Oncol Hematol Rev; 2014; 10(1):42-47. PubMed ID: 24932461
[TBL] [Abstract][Full Text] [Related]
3. Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.
Choi E; Buie J; Camacho J; Sharma P; de Riese WTW
Res Rep Urol; 2022; 14():87-108. PubMed ID: 35386270
[TBL] [Abstract][Full Text] [Related]
4. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
Lycette JL; Bland LB; Garzotto M; Beer TM
Clin Genitourin Cancer; 2006 Dec; 5(3):198-205. PubMed ID: 17239273
[TBL] [Abstract][Full Text] [Related]
5. Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture.
Wilson HC; Shah SI; Abel PD; Price P; Honeyfield L; Edwards S; Abel RL
Cent European J Urol; 2015; 68(2):165-8. PubMed ID: 26251735
[TBL] [Abstract][Full Text] [Related]
6. Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review.
Coelingh Bennink HJT; Krijgh J; Egberts JFM; Slootweg M; van Melick HHE; Roos EPM; Somford DM; Zimmerman Y; Schultz IJ; Clarke NW; van Moorselaar RJA; Debruyne FMJ
Endocr Connect; 2022 Dec; 11(12):. PubMed ID: 36283120
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
Walker LM; Tran S; Robinson JW
Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.
Coss CC; Jones A; Parke DN; Narayanan R; Barrett CM; Kearbey JD; Veverka KA; Miller DD; Morton RA; Steiner MS; Dalton JT
Endocrinology; 2012 Mar; 153(3):1070-81. PubMed ID: 22294742
[TBL] [Abstract][Full Text] [Related]
9. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for prostate cancer.
Sharifi N; Gulley JL; Dahut WL
JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
[TBL] [Abstract][Full Text] [Related]
13. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
14. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
15. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.
Fujimura T; Takayama K; Takahashi S; Inoue S
Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29360794
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Stein MN; Hussain M; Stadler WM; Liu G; Tereshchenko IV; Goodin S; Jeyamohan C; Kaufman HL; Mehnert J; DiPaola RS
Clin Genitourin Cancer; 2016 Feb; 14(1):22-7. PubMed ID: 26476589
[TBL] [Abstract][Full Text] [Related]
18. Background to and management of treatment-related bone loss in prostate cancer.
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
20. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
